Borage Seed Oil (Borago officinalis)

Borage seed oil is extracted from Borago officinalis seeds and is the richest botanical source of gamma-linolenic acid (GLA), comprising 18–26% of its fatty acid profile. GLA is elongated to dihomo-gamma-linolenic acid (DGLA) in the body, which competes with arachidonic acid at cyclooxygenase enzymes to reduce pro-inflammatory eicosanoid synthesis.

Category: Seed Oils Evidence: 2/10 Tier: Moderate
Borage Seed Oil (Borago officinalis) — Hermetica Encyclopedia

Origin & History

Borage seed oil is extracted from the seeds of Borago officinalis L., a flowering plant native to the Mediterranean region. The oil is obtained through cold pressing or supercritical CO₂ extraction methods and is characterized by high concentrations of gamma-linolenic acid (GLA), linoleic acid, and oleic acid.

Historical & Cultural Context

The research dossier does not contain information about traditional or historical use of borage seed oil in traditional medicine systems.

Health Benefits

• May support skin health in atopic dermatitis - mixed evidence from RCTs showing improvement in subgroups with elevated DGLA levels
• Demonstrates anti-proliferative effects against leukemia cells (HL-60) with IC₅₀ values of 0.3-2.3 μL/mL in laboratory studies
• Shows potential for reducing skin pigmentation - one RCT found significant melasma reduction after 6-8 weeks of topical use
• Exhibits antimutagenic effects and DNA protective activity in laboratory studies
• May improve metabolic health when combined with quercetin - one study showed improved glucose tolerance and insulin resistance

How It Works

GLA from borage seed oil is converted by delta-6-desaturase and elongase enzymes into DGLA, which competes with arachidonic acid for COX-1 and COX-2 enzyme binding, shifting eicosanoid production toward less inflammatory series-1 prostaglandins (PGE1) and away from pro-inflammatory series-2 prostaglandins (PGE2) and leukotriene B4. DGLA also partially inhibits 5-lipoxygenase, reducing leukotriene synthesis. In vitro, borage oil's GLA content induces apoptosis in HL-60 leukemia cells with IC₅₀ values of 0.3–2.3 μL/mL, potentially via lipid peroxidation and mitochondrial membrane disruption.

Scientific Research

Clinical evidence includes a large RCT (n=140) showing no significant difference between borage oil and placebo for atopic dermatitis overall, though a subgroup with elevated DGLA levels showed improvement. A smaller trial (n=21) demonstrated significant melasma reduction with 1% lipase-treated borage oil cream after 6-8 weeks. A systematic review identified 12 controlled trials for atopic dermatitis applications.

Clinical Summary

Randomized controlled trials examining borage seed oil for atopic dermatitis have produced mixed results; a subset of trials report statistically significant improvements in SCORAD indices and transepidermal water loss in participants with elevated baseline DGLA levels, suggesting a pharmacogenomic responder subgroup. A double-blind RCT using 500 mg/day borage oil in adults with mild-to-moderate atopic dermatitis showed modest but not universally significant reductions in symptom scores compared to placebo. Anti-proliferative effects against HL-60 leukemia cells (IC₅₀ 0.3–2.3 μL/mL) are well-documented in vitro but have not been replicated in human clinical trials. Overall, the evidence base is preliminary to moderate; large, well-powered RCTs are lacking across most proposed indications.

Nutritional Profile

Borage Seed Oil is composed predominantly of fatty acids (~95-99% of total composition). The defining characteristic is its exceptionally high gamma-linolenic acid (GLA) content at 18-26% of total fatty acids — the richest plant-derived source of GLA available commercially. Full fatty acid breakdown: linoleic acid (omega-6) 35-38%, GLA (omega-6, 18:3n-6) 18-26%, oleic acid (omega-9) 14-20%, palmitic acid (saturated) 9-12%, stearic acid (saturated) 3-5%, eicosenoic acid (omega-9, 20:1) 3-5%, erucic acid (omega-9, 22:1) 1.5-3.5%, nervonic acid (24:1) ~1-2%, alpha-linolenic acid (omega-3) <0.5%. Minor bioactive components include tocopherols (primarily gamma-tocopherol and alpha-tocopherol) at approximately 50-100 mg/100g total, providing antioxidant stability. Phytosterols are present at approximately 200-400 mg/100g, predominantly beta-sitosterol (~60%), campesterol (~20%), and stigmasterol (~15%). Pyrrolizidine alkaloids (PAs) — specifically thesinine and other unsaturated PAs — are detectable in trace amounts (~1-10 ppm) in unrefined oils; pharmaceutical and cosmetic grades are typically processed to reduce PA content below regulatory thresholds (European Medicines Agency guidance: <1 μg/day PA intake). Caloric density is approximately 884 kcal/100g (standard for refined plant oils). GLA bioavailability: orally consumed GLA from borage oil is efficiently converted to dihomo-gamma-linolenic acid (DGLA) in tissues, with conversion rates depending on individual delta-6-desaturase enzyme activity; topical bioavailability is limited but measurable via transdermal absorption studies. No meaningful protein, carbohydrate, fiber, or water-soluble vitamin content is present in the refined oil form.

Preparation & Dosage

Clinical trials have used oral borage oil supplementation over 12-week periods for atopic dermatitis, though specific dosages were not reported in available research. For topical skin brightening, 1% lipase-treated borage oil in cream formulations was studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Evening primrose oil, Fish oil, Vitamin E, Black currant seed oil

Safety & Interactions

Borage seed oil is generally well tolerated at typical supplemental doses of 500–3000 mg/day, with mild gastrointestinal upset (nausea, soft stools) being the most commonly reported adverse effect. Unsaturated pyrrolizidine alkaloids (UPAs) present in non-refined borage preparations carry hepatotoxic and potentially carcinogenic risk; supplements should specify 'PA-free' or hepatotoxic-alkaloid-free certification. Borage oil may potentiate anticoagulant and antiplatelet medications (e.g., warfarin, aspirin, clopidogrel) due to PGE1-mediated platelet aggregation inhibition, warranting clinical monitoring. Use is contraindicated in pregnancy due to potential uterotonic prostaglandin effects, and safety in lactation has not been established.